londamocitinib

Londamocitinib is a potent, highly selective small molecule inhibitor of **Janus kinase 1 (JAK1)**, developed for the treatment of moderate-to-severe asthma not adequately controlled by inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) therapy. It demonstrates sub-nanomolar potency for JAK1 (IC50 = 0.54 nM), with anti-inflammatory activity and is currently in Phase 2 clinical development, primarily as an oral therapy for asthma and airway diseases. Londamocitinib is also referenced by the code AZD4604 and its xinafoate salt formulation. The drug was initially developed by AstraZeneca[1][3][5][9][10].

Brand names

londamocitinib

Other names

(R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide1-piperazineacetamide, n-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.-(methoxymethyl)-4-methyl-, (.alpha.r)AZD4604 xinafoateAZD-4604 xinafoateAZD 4604 xinafoatelondamocitinib xinafoate